Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jade Biosciences, Inc. - Common Stock (NQ:JBIO)

20.89 -0.61 (-2.84%)

Streaming Delayed Price Updated: 3:55 PM EDT, May 28, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	446,441
Open	21.56
Bid (Size)	20.87 (800)
Ask (Size)	20.91 (400)
Prev. Close	21.50
Today's Range	20.33 - 21.62
52wk Range	6.565 - 28.00
Shares Outstanding	28,985,019
Dividend Yield	11.49%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

May 26, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

May 26, 2026

From Jade Biosciences

Via GlobeNewswire

Performance

YTD	+47.5%	+47.5%
1 Month	-22.2%	-22.2%
3 Month	+44.1%	+44.1%
6 Month	+67.4%	+67.4%
1 Year	+183.4%	+183.4%

More News

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗

May 13, 2026

Via The Motley Fool

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗

May 13, 2026

Via The Motley Fool

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗

May 13, 2026

Via The Motley Fool

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 07, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 23, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

April 22, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 06, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences to Participate in Upcoming Conferences

February 11, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces $45 Million Private Placement

December 15, 2025

From Jade Biosciences

Via GlobeNewswire

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

November 08, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences to Participate in Upcoming Conferences

November 03, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

October 17, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

October 07, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces $135 Million Private Placement

October 07, 2025

From Jade Biosciences

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 01, 2025

Via Benzinga

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

September 02, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences to Participate in Upcoming Conferences

August 25, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Posts Wider Loss in Q2 ↗

August 13, 2025

Via The Motley Fool

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025

From Jade Biosciences

Via GlobeNewswire

Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

July 17, 2025

Via Benzinga

Frequently Asked Questions

Is Jade Biosciences, Inc. - Common Stock publicly traded?

Yes, Jade Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Jade Biosciences, Inc. - Common Stock trade on?

Jade Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Jade Biosciences, Inc. - Common Stock?

The ticker symbol for Jade Biosciences, Inc. - Common Stock is JBIO on the Nasdaq Stock Market

What is the current price of Jade Biosciences, Inc. - Common Stock?

The current price of Jade Biosciences, Inc. - Common Stock is 20.89

When was Jade Biosciences, Inc. - Common Stock last traded?

The last trade of Jade Biosciences, Inc. - Common Stock was at 05/28/26 03:55 PM ET

What is the market capitalization of Jade Biosciences, Inc. - Common Stock?

The market capitalization of Jade Biosciences, Inc. - Common Stock is 605.50M

How many shares of Jade Biosciences, Inc. - Common Stock are outstanding?

Jade Biosciences, Inc. - Common Stock has 605M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.